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Identifying rare, highly penetrant risk mutations may be an important step in dissecting the molecular etiology of
schizophrenia. We conducted a gene-based analysis of large (>100 kb), rare copy-number variants (CNVs) in the
Wellcome Trust Case Control Consortium 2 (WTCCC2) schizophrenia sample of 1564 cases and 1748 controls all
from Ireland, and further extended the analysis to include an additional 5196 UK controls. We found association
with duplications at chr20p12.2 (P 5 0.007) and evidence of replication in large independent European schizo-
phrenia (P 5 0.052) and UK bipolar disorder case-control cohorts (P 5 0.047). A combined analysis of Irish/UK
subjects including additional psychosis cases (schizophrenia and bipolar disorder) identified 22 carriers in
11 707 cases and 10 carriers in 21 204 controls [meta-analysis Cochran–Mantel–Haenszel P-value 5 2 3
1024; odds ratio (OR)5 11.3, 95% CI 5 3.7,1]. Nineteen of the 22 cases and 8 of the 10 controls carried duplica-
tions starting at 9.68 Mb with similar breakpoints across samples. By haplotype analysis and sequencing, we
identified a tandem ∼149 kb duplication overlapping the gene p21 Protein-Activated Kinase 7 (PAK7, also
called PAK5) which was in linkage disequilibrium with local haplotypes (P 5 2.5 3 10221), indicative of a
singleancestralduplication event. Weconfirmed thebreakpoints in8/8carriers tested and found co-segregation
of the duplication with illness in two additional family members of one of the affected probands. We demonstrate
that PAK7 is developmentally co-expressed with another known psychosis risk gene (DISC1) suggesting a po-
tential molecular mechanism involving aberrant synapse development and plasticity.
INTRODUCTION
Schizophrenia [MIM 181500] is a poorly understood, but severe,
heritable mental disorder with a lifetime risk of 1%. The emer-
ging genetic architecture includes a spectrum of risk variation
from rare mutations of large effect, to common risk variants of
small effect [odds ratio (OR) ,1.15] which collectively account
for at least25% of susceptibility (1–3).Through genome-wide as-
sociation study (GWAS) and subsequent meta-analysis, more
than 20 independent common loci have been confirmed, but
there are likely to be many more (4–6). A much smaller number
of rare mutations of moderate or large effect have been identified,
but these will be particularly important in facilitating dissection of
the risk phenotype in model systems (7).
The list of rare, highly penetrant schizophrenia mutations
(OR ¼ 2–30) includes recurrent de novo copy-number variants
(CNVs) involving deletions or duplications of large, genomic
regions (.100 kb) (8,9), but also the accumulation of different
CNV events at specific loci implicating single genes (NRXN1
[MIM 600565] (10–12) and VIPR2 [MIM 601970]) (13,14).
Almost all of the confirmed CNVs are also risk factors for other
psychiatricordevelopmentalphenotypes [e.g. intellectualdisabil-
ity, attention deficit hyperactivity disorder (ADHD), autism]
(15,16). This is in keeping with epidemiological and GWAS
data supporting shared genetic liability between schizophrenia
and other psychiatric disorders, in particular bipolar disorder
(17–19). As current findings explain a modest proportion of
total schizophrenia susceptibility, expanding the number of risk
mutations will be important in understanding molecular etiology
but also the relationships between these clinical disorders (20).
We report a gene-based analysis of large (.100 kb), rare
[,1% minor allele frequency (MAF)] CNVs in the Wellcome
Trust Case Control Consortium 2 (WTCCC2) schizophrenia
sample of 1564 cases and 1748 controls, all from Ireland. We
find evidence of association with duplications at 20p12.2 and
further support in a large independent European sample. All of
the carriers were from the British Isles and an extended analysis
including 32 911 Irish/UK subjects provided further association
support. By haplotype analysis and sequencing, we show that the
CNV is not the result of repeated de novo events and is an inher-
ited risk mutation potentially inherited from a single European
ancestor. This accords with emerging evidence for rare CNVs
that are population-specific and associated with substantial
illness risk (21,22), consistent with the ‘Clan Genomics’
concept (23). The mutation involves a tandem duplication of
148 951 bp at chr20:9,684,767–9,833,717(hg18) overlapping
the gene p21 Protein-Activated Kinase 7 (PAK7, also known
as PAK5). Other PAK family members modulate synaptic
network development through a signaling pathway regulated
by the schizophrenia risk gene DISC1 (24). We demonstrate
that PAK7 is co-expressed with DISC1 in developing brain and
further investigation of the role of the mutation in synaptic
mechanisms salient to schizophrenia is warranted.
RESULTS
Discovery phase evidence of association at four loci
We observed evidence of association (P , 0.05) at four loci in
the Irish discovery dataset of 1564 cases and 1748 controls;
20p12.2(PAK7 [MIM 608038]); 2cen-q13 (ANKRD36B,
COX5B [MIM 123866]; ACTR1B [MIM 605144]); 3p25.1
(MRPS25 [MIM 611987], ZFYVE20 [MIM 609511]) and a pre-
viously confirmed schizophrenia risk locus [chr1q.21 (CHD1L
[MIM 613039]) locus (8,9)]. Association results for the three
novel loci are presented in Table 1. To improve our estimate of
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the population frequency of what are rare events, we examined
the three novel loci in an extended control sample (n ¼ 6944) in-
cluding UK controls from WTCCC2 [2533 controls from the UK
National Blood Service (NBS) and 2663 from the UK 1958 Birth
Cohort (58BC)]. We identified chr1q21.1 risk duplications in
four cases, chromosome 15q13.3 deletions in three cases and a
single case with the large 22q11.2 deletion with no similar
events seen in controls from the discovery analysis. Details of
our findings at all previously reported schizophrenia CNV risk
loci, with locus coordinates, are provided in Supplementary
Material, Table S3a. Further, we provide details of all large
(.100 kb), rare CNVs identified in our discovery sample in
cases and controls (Supplementary Material, Table S3b).
Replication phase association evidence at chr20p12.2
Three loci were carried forward for replication (Table 1) in the
independent International Schizophrenia Consortium (ISC)
dataset of 3111 cases and 2267 controls from the UK, Portugal,
Sweden and Bulgaria (8). Only the chr20p12.2 locus containing
p21 Protein-Activated Kinase 7 (PAK7, also known as PAK5)
showed evidence for association in the replication sample,
with six duplication events, all in UK cases, and none in controls
(P ¼ 0.052). Because this is a rare event, and absent in the
control population, the reported association result was the
most significantP-value obtainable without a larger sample size.
As all of the carriers were identified in samples from the
British Isles, we investigated the locus for additional evidence
of association in an independent sample of bipolar disorder in
the WTCCC1 (n ¼ 1697) (25) and University College London
(UCL) (n ¼ 546) samples (26). The controls included independ-
ent UK controls from the UCL study (n ¼ 510) and 10 259 cases
ascertained for nonpsychiatric disorders in WTCCC1. We iden-
tified four duplication carriers in cases and five carriers in the
control sample, provided further nominal evidence of associ-
ation (P ¼ 0.047).
We performed a combined analysis of all Irish/UK subjects in-
cluding additional psychosis cases from the CLOZUK study (27)
(n ¼ 6223) and independent controls from the WTCCC2 UK
control sample (n ¼ 7703) (28,29). Combining the evidence
across studies, under the assumption of the same effect on risk
in each strata, gave a meta-analysis Cochran–Mantel–Haenszel
(CMH) P-value ¼ 2 × 1024 (OR ¼ 11.3, 95% CI ¼ 3.7, 1)
with 22 carriers in 11 707 psychosis cases and 10 carriers in 21
204 controls.
Evidence for a single founder risk mutation at PAK7
Based on the array data, we examined the inferred breakpoints
for the chr20p12.2 duplications, and the estimated start and
stop coordinates for the 32 duplication carriers (Fig. 1, Supple-
mentary Material, Table S5). Nineteen of the 22 duplication car-
riers in the cases and 8 of 10 carriers from the controls exhibited
duplications of 132–146.5 kb with very similar start positions
(9.68 Mb), apparently similar breakpoints across samples
and no evidence of flanked segmental duplications. The evi-
dence for association at the locus in the Irish/UK sample
appeared to be driven by these duplication cases. The remaining
five individuals carried duplications occurring on differentT
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haplotype backgrounds and are likely to represent different
molecular events.
To explore whether this could represent a single ancestral mu-
tation event, we examined haplotype sharing in the five Irish case
samples in linkage disequilibrium (LD) blocks (termed Hap
Block 1 and Hap Block 2) immediately 5′ and 3′ of the inferred
duplication. Haplotypes were phased in PLINK with a probabil-
ity .0.98. All five Irish cases carried a copy of the same haplo-
type in both Hap Block 1 (CCTT, f ¼ 0.188) and Hap Block 2
(TCAA, f ¼ 0.208) (Supplementary Material, Tables S6 and
S7). We extended the analysis to include 18 of the 22 UK carriers
(as these had been genotyped on the same Affymetrix platform)
and found that all carried copies of the CCTT and TCAA haplo-
types flanking the duplication (Supplementary Material,
Table S8). Given the low level of LD between these blocks
(D′ ¼ 0.22, r2 ¼ 0.02) the probability of making these observa-
tions if the duplication was the result of repeated de novo muta-
tions is extremely low (P ¼ 2.5 × 10221), providing support for
a single ancestral duplication event. We did not find an increased
level of relatedness among the Irish PAK7 duplication carriers
compared with the level of relatedness of random Irish indivi-
duals, arguing against a very recent event (see Supplementary
Material, Fig. S1).
Next, we confirmed the duplication event in one individual
(IRL_101) using an Agilent custom designed comparative
genomic hybridization (CGH) microarray with high probe
density in the PAK7 region. The breakpoints identified by CGH
(chr20:9,684,902–9,833,151) map closely to those predicted by
the SNP array analyses (chr20:9,685,413–9,831,947; Supplemen-
tary Material, Fig.S2).The event overlaps exon 1 and enhancer and
promoter regions adjacent to exon 1 in all four known PAK7
transcripts, and exon 2 in two alternative transcripts and is
absent from the Database of Genomic Variants (http://projects.
tcag.ca/variation/). By capillary sequencing this individual, we
identified a tandem duplication of 148 951 bp at chr20:9,684,
767–9,833,717(hg18) with a 15 bp sequence inserted between
the first and second copies of the repeated sequence (Fig. 2). By se-
quencing the five remaining Irish carriers and two of the UK car-
riers (SCOT_101, SCOT_201), we confirmed that all shared
exactly the same breakpoints with the same 15 bp sequence
Figure1. Inferred position of duplication events at the chr20p12.2 locus in build hg18. SZ, schizophrenia. BD, bipolar disorder. See Supplementary Material, Table S5
for exact start/stop coordinates. Duplications in controls are colored light blue and SZ or BP cases are colored dark blue.
Figure2.Capillary sequence of the unique region in the middle of the two copies of the tandem repeat sequence at thePAK7duplication. The first copy of the sequence
ends at chr20:9,833,717(hg18) and the second copy starts with sequence from chr20:9,684,767(hg18), thereby defining the breakpoints. A 15 bp sequence is present
between the two copies.
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inserted between the two copies of the repeat sequence, suggesting
that this represents the same duplication event.
Assessment of additional family members of carriers
We were able to access additional family members of two cases to
test for evidence of co-segregation of the duplication with illness
(see Fig. 3). In the family of IRL-101, there were three other sur-
viving siblings, none of whom had a diagnosis of schizophrenia or
a related major mental disorder. One sister (IRL_102) agreed to be
tested. She had experienced a depressive episode after bereave-
ment and did not carry the duplication.Bygoingback to the origin-
al GWASdata, we identified another Irishcase (IRL_601) that had
been excluded from the primary analysis because they are related
to IRL_101 based on a proportion of identity-by descent estimated
at 0.033. IRL_601 is a female patient with a history of Schizo-
affective Disorder. She is the youngest in a sibship of five children
of which four were affected with a major psychotic disorder. We
confirmed that two affected brothers (IRL_603 (bipolar I dis-
order), IRL_604 (psychotic disorder, not otherwise specified))
also carry the PAK7 duplication. The remaining affected brother
[IRL_602 (bipolar I disorder)] died by suicide. We tested one of
the eight offspring of IRL_601, and this unaffected individual
did not carry theduplication. In the SCOT_1 family, weconfirmed
that the duplication was inherited from the mother (SCOT_103).
Neither of the parents was affected clinically, but there was a
family history of depression in both families, and a brother with
a history of psychosis did not carry the duplication (SCOT_104).
Is the mutation present in other European ancestry
populations?
To assess whether the mutation was exclusive to the British Isles
or present elsewhere in Europe, we examined additional
European populations. Details of the cohorts analyzed are
included in Supplementary Material, Table S1. The estimated
control frequency for the mutation in the UK/Irish population
is low (f ¼ 0.037%) and most of these cohorts were underpow-
ered to provide an accurate frequency estimate for what is a
rare event. We failed to identify any carriers in large Icelandic
(.72 000 individuals) and Finnish samples (3800 indivi-
duals), but did find carriers in populations from the Eastern
USA, the Netherlands, Sweden and Denmark. We were able to
unambiguously phase haplotypes in five US control carriers
with available Affymetrix data, confirming that all of these indi-
viduals shared the same haplotype background as the Irish/UK
cases, suggesting that they carry the same mutational event al-
though the samples were not available for confirmatory sequen-
cing. The other European samples were genotyped on a different
array platform and where we could definitively phase haplo-
types; this confirmed the same haplotype background. These
data suggest that the mutation is present in other European popu-
lations. The limited number of cases available precluded formal
association analyses, but we identified four additional cases with
the duplication in Dutch, Danish and Swedish cohorts. Informa-
tion on the clinical characteristics, illness course, co-morbidity
and family history for all mutation case carriers is provided in
Supplementary Material, Table S9.
Functional investigation of PAK7
The p21-activated kinases (PAKs) are a family of serine/threo-
nine protein kinases, which are regulated by the Rho family of
small G proteins and are involved in multiple intracellular sig-
naling pathways. Six PAK genes are expressed in human and
based on their regulatory functions are classified into Group I
(PAK 1-3) and Group II (PAK4-6) members (30). Group I
PAKs are activated by RAC-PAK signaling to promote axon
connectivity, and synapse formation, in the developing brain
in a pathway regulated by another schizophrenia risk gene
DISC1 [MIM:60521] (31). Aberrant synaptic network develop-
ment and maintenance represents a plausible molecular mechan-
ism for psychosis susceptibility and mutations involving other
Group I PAKs (PAK2 (the 3q29 microdeletion syndrome locus
[MIM 609425]) and PAK3 [MIM:300558]) are known to be
associated with neurodevelopmental syndromes characterized
by psychosis (32). PAK7 is a brain-specific isoform within the
cell it is localized to filipodia, where it has been shown to
promote the induction of neurite outgrowth, filopodium forma-
tion and synaptic vesicle trafficking (33). The Group II PAKs, in-
cluding PAK7, differ structurally from Group I members and
their mechanism of activation requires clarification.
To test whetherPAK7may be under similar regulatory control
to Group I PAKs during early brain development, we investi-
gated the relationship between PAK7 and DISC1. Examining
Brainspan data (brainspan.org), we identify significant negative
correlation between DISC1 and PAK7 expression in whole
human brain throughout life (r2 ¼ 20.297 to 0.867). The stron-
gest correlations are for the first and last trimester of pregnancy
and the first 5 years of life, with the level of correlation falling
through adulthood. In a co-immunoprecipitation experiment,
we confirmed interaction between PAK7 and DISC1 in synapto-
neurosomal preparations from full mouse brain at postnatal day
8–10 [(P8–10); Fig. 4A]. Next, we ran the reciprocal
Figure 3. Familial pedigrees for patients from three families (IRL_6, IRL_1,
SCOT_1) who were found to be positive for PAK7 duplications. The index indi-
vidual in each family screened is indicated with an arrow. Individuals positive
(PAK7 + VE) or negative (PAK72 VE) for PAK7 are indicated. Filled
symbols indicate individuals with psychotic disorders (SCZ, schizophrenia;
SCA, schizoaffective disorder; BPA, bipolar affective disorder; PDNOS, psych-
otic disorder not otherwise specified). Partial vertically shaded symbol indicates
depressive disorder (DEP, depression). Partial horizontal shaded symbol indi-
cates learning disability (LD). Cause of death where known: SUIC, suicide;
BA, birth asphyxia; CT, cerebral tumor.
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experiment and demonstrated immunoprecipitation of DISC1
followed by immunostaining of the eluate with antiPAK7
(Fig. 4B). Finally, we explored the regional and temporal evi-
dence for co-expression in brain regions implicated in schizo-
phrenia etiology (hippocampus and cortex). In this analysis,
we co-immunostained PAK7 and DISC1 in P7 and adult
(.P60) mice. We find clear overlap in perisomal puncta,
which confirms that the two proteins interact at the synapse, par-
ticularly in adult mouse brain (Fig. 4D–O). This suggests that
PAK7 is developmentally co-expressed with DISC1 and may
have a specific functional role at the synapse.
DISCUSSION
We report evidence that rare, chr20p12.2 duplications increase
risk for the major psychotic disorders, schizophrenia and
bipolar disorder. Previous schizophrenia studies have identified
at least eight rare CNVs of strong effect (genotypic relative risks
of 4–20) (5). Most of these CNVs have been identified because
they recur in the population, either as relatively large events im-
plicating many genes and arising from nonallelic homologous
recombination (NAHR), or through the accumulation of
different, generally de novo mutations at a single locus (e.g.
NRXN1, VIPR2). At the PAK7 locus, we identified a single
founder event with a 15 bp sequence inserted between the two
copies of the tandem duplication. From the 1000 Genomes
Project data, most tandem duplications of this type are formed
by fork stalling and template switching as detailed in the
micro-homology-mediated break-induced replication model
(34,35).
We identified 2653 genes affected by a CNV (.100 kb but
,10 Mb) in at least one individual in our study. However,
only 382 genes had the four or more overlapping CNVs required
to achieve P, 0.05 in our discovery sample. Based on our data,
the overall contribution of CNVs to psychosis susceptibility risk
is difficult to estimate as we could not exclude rarer or smaller
events. Ongoing CNV analysis of the Psychiatric Genomics
Consortium dataset will be important in more comprehensively
investigating rare, large CNV events (17).
By haplotype analysis and sequencing, we established that the
association is driven by a149 kb duplication at the genePAK7
with a likely common European ancestor. Inherited mutations
have been described contributing to other neurological
disorders, but their relative contribution to schizophrenia
Figure 4.PAK7 and DISC1 interact in mouse brain synapses. (A) Immunoprecipitation of PAK7 and DISC1 from synaptoneurosomal extracts of adult mouse brains.
The extract was immunoprecipitated for PAK7 and the eluate was immunostained for DISC1. (B) Reciprocal experiment described in A: immunoprecipitation of
DISC1 followed by immunostaining of the eluate with antiPAK7. In both A and B, the samples immunoprecipitated with control IgG showed no signal, showing
the specificity of the PAK7–DISC1 interaction. An additional control in (C) shows that the brain extracts before immunoprecipitation have the same amount of
loading control (b-actin). (D–N) Immunostaining for PAK7 (green) and DISC1 (red) in brain sections containing Hippocampus and Cortex of P7 (D–I) and
Adult (J–O) mice. The experiment shows an overlapping (yellow) of PAK7 and DISC1 in puncta, confirming a synaptic interaction between the two proteins.
The co-localization is particularly evident in the adult (J–O) preparation.
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susceptibility is unknown (21,22,36). Such events are likely to be
recent in origin and differentiated between populations making
them difficult to replicate across diverse collections using stand-
ard gene association methods in large multicohort CNV studies
(37–39). Although a single variant is unlikely to influence the
overall population risk for a disorder, founder risk mutations
can be identified through association analysis in specific popula-
tions. By examining cases excluded, through relatedness QC,
from our original Irish GWAS dataset, we identified an addition-
al duplication carrier related at a distance of five meioses to one
of the index cases. Within the family of this additional carrier, we
found evidence of co-segregation of the duplication with psych-
osis in two affected siblings. Identifying cryptic relationships
between individuals in available GWAS datasets may be
helpful in identifying extended pedigrees for analysis as a com-
plementary approach to existing association methods.
The risk duplication identified in this study overlaps the first
two exons and enhancer and promoters regions in the known
transcripts of PAK7. Because PAK7 is exclusively brain
expressed, the impact of the duplication on gene expression
and the genetic mechanism involved are yet to be determined.
This is important as we identified other larger duplication
events at the locus in two control samples, but do not know if
these would have the same or different effects on gene function.
From existing animal models of PAK7, we do know that knock-
out mice are viable with no obvious developmental abnormal-
ities but PAK6/PAK7 double knockout mice show behavioral
and learning deficits suggesting functional redundancy
between these isoforms (40). Genomic studies in carriers of
the founder mutation will be important as additional risk variants
or mutations (e.g. inDISC1 orPAK6) may be contributing to risk
in this extended pedigree.
The PAK7 risk mutation is rare, but based on data from the
British Isles, we estimate the exposed attributable risk for car-
riers is likely to be substantial (41). We attempted to date the
origin of the duplication by examining haplotype sharing in
this genomic region. After characterizing the haplotype patterns
in the region, we were unable to make robust inference: further
family data will be required to accurately phase haplotypes for
this rare event.
Almost all of the risk CNVs identified to date in the schizo-
phrenia literature also increase susceptibility to other develop-
mental phenotypes including intellectual disability, autism and
seizure disorder. Only four of our cases received a full cognitive
assessment (including IQ measurement), and all were assessed
as being within the normal range of cognitive function. One in-
dividual had a history of co-morbid language delay and
another had a history of seizure disorder. Although most of the
cases had schizophrenia, seven had bipolar disorder or schizo-
affective disorder. This is in keeping with evidence of shared
genetic etiology between these disorders, although the evidence
for CNV involvement in bipolar disorder has until now been
more equivocal (42,43). Having identified carriers of the dupli-
cation in control cohorts, we were interested in testing whether
‘control’ individuals had psychiatric or developmental pheno-
types. In almost all studies (including the individual WTCCC1
studies), controls were not screened for mental disorder and
little if any developmental information was available. Within
the UK and Ireland health biobank, data are now becoming avail-
able on a sufficiently large scale to allow us to directly examine
the phenotypic implications of carrying rare events in the general
population and this is one of future goals (e.g. The Generation
Scotland Family Health Study, UK Biobank and ‘Growing Up
in Ireland’ Study). Further clinical and genetic assessment of
patient carriers and their families will also be important in quan-
tifying the penetrance and range of phenotypic expression of the
PAK7 duplication.
Schizophrenia is a neurodevelopmental disorder and a disease
model involving aberrant synaptic network development has
been proposed (44). Group I PAKs play a role in the development
of these networks through a signaling pathway regulated by an
established susceptibility gene (DISC1) (45). PAK7 is a brain-
specific isoform, within the cell it is localized to filipodia,
where it has been shown to promote the induction of neurite out-
growth, filopodium formation and synaptic vesicle trafficking
(33). To clarify its mechanism of activation, we performed func-
tional studies that confirmed interaction between PAK7 and
DISC1, suggesting that this gene may be under similar regulatory
control to other PAK family members. Furthermore, this inter-
action occurs at the synapse and is particularly evidence in
adult mouse brain suggesting a role in synaptic plasticity.
In conclusion, we have identified a psychosis risk duplication
at the gene PAK7, with evidence that it is inherited from a
common ancestor. The gene functions in the development and
maintenance of synaptic networks and may be under the regula-
tory control ofDISC1. Many of the cases segregating the DISC1
translocation in the original Scottish schizophrenia pedigree
were affected with schizoaffective disorder or mood disorders
as was the case in the largest PAK7 pedigree we investigated,
and we also found evidence for association with bipolar disorder
(46). This suggests a broader molecular risk mechanism for
psychosis. A critical next step will be to understand how the du-
plication impacts on gene expression and function so that it can
be investigated in model systems. As PAK7 is exclusively
brain-expressed, this will require further experimental work.
MATERIALS AND METHODS
Study subjects
The discovery sample included 1564 cases and 1748 controls
from the Irish Schizophrenia Genomics Consortium/WTCCC2
GWAS study which has previously been described (47). Partici-
pants, from the Republic of Ireland or Northern Ireland, were
interviewed using a structured clinical interview and diagnosis
of schizophrenia (n ¼ 1418) or a related disorder [schizoaffect-
ive disorder (n ¼ 182); schizophreniform disorder (n ¼ 6)] was
made by the consensus lifetime best estimate method using
DSM-IV criteria. Control subjects were ascertained with
written informed consent from the Irish GeneBank and repre-
sented blood donors from the Irish Blood Transfusion Service.
Cases and controls met the same ethnicity criteria (Irish origin
with all four grandparents born in Ireland or the UK). To
improve our estimate of the population frequency of what are
rare events, we examined nominally significant loci in an
extended control sample (n ¼ 6944) including UK controls
from WTCCC2 [2533 controls from the UK National Blood
Service (NBS) and 2663 from the UK 1958 Birth Cohort
(58BC)] (28).
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The first phase of replication examined nonoverlapping sub-
jects from the ISC dataset (8). To follow-up evidence of associ-
ation in the British Isles, we performed further association
analysis in bipolar disorder cases and controls from the UK/
Ireland. The WTCCC1 bipolar disorder sample included 1697
cases recruited throughout the UK. Most of the cases had a diag-
nosis of bipolar I disorder (71%) or schizoaffective disorder
(15%). Controls were nonpsychiatric disease case participants
in the WTCCC1 study (n ¼ 10 259) (25). The UCL bipolar dis-
order sample included 546 individuals (97% bipolar I disorder)
and comparison subjects (n ¼ 510) with no personal or first-
degree history of any mental disorder and from a similar UK or
Irish ancestry, based on the origin of all four grandparents (26).
Finally, in an extended analysis, we included additional
psychosis cases and controls from the UK. The additional psych-
osis cases were of Caucasian origin and came from the CLOZUK
sample (n ¼ 6223) (27). The CLOZUK sample consists of
patients taking the antipsychotic medication Clozapine, a drug
reserved for the treatment-resistant psychosis patients in the
UK. The remaining control subjects were ascertained as
described in previous WTCCC2 studies from the UK National
Blood Service (NBS) (n ¼ 2533); the UK 1958 Birth Cohort
(n ¼ 2663); the People of the British Isles (POBI) study and
from (28,29). We also investigated additional European ancestry
cohorts for evidence of the PAK7 duplication and details on the
samples tested, case and/or control numbers and genotyping
platform are provided in Supplementary Material, Table S1
(5,9,48,49).
CNV calling and validation
We report a schizophrenia study investigating large (.100 kb),
rare (,1% MAF in all samples) CNVs using data from the
WTCCC2. All discovery samples were genotyped using the
Affymetrix 6.0 platform either at the Affymetrix (Santa Clara,
CA, USA) or at the Broad Institute (Cambridge, MA, USA) la-
boratories. Samples were processed using the WTCCC2 pipeline
and quality control details have been reported previously
(27,47).
CNV calls were created using Birdseye from Birdsuite
(version 1.5.5) (50) for autosomes only, and we excluded calls
where lengths were ,100 kb or .10 Mb, or LOD score ,10.
We excluded CNVs with at least 50% overlap with a region
copy-number variable in at least 1% of samples; individuals
with .30 CNV calls or a total event length .10 Mb and calls
for samples from plates containing fewer than 40 samples (Sup-
plementary Material, Table S2). Calls with a copy number of 0 or
1 were considered to be deletions and calls with a copy number of
3 or 4 were considered duplications.
For the replication analysis, the ISC data were called using the
same calling protocol as in the discovery analysis. Details on
genotyping platforms used for the other samples are provided
in Supplementary Material, Table S1. For the identified PAK7
risk duplication, we performed standard qPCR validation of
the CNV calls in the discovery sample (Supplementary Material,
Table S4). Verifying the presence of CNVs by this method
addresses sensitivity, but not the specificity of CNV calling.
To test the specificity and sensitivity of calling across genotyp-
ing platforms, we examined probe intensity data for 6542
control subjects who had been genotyped on Affymetrix 6.0
and Illumina 1.2M-Duo arrays as part of the wider WTCCC2
study. We called CNVs on the Illumina platform using Quan-
tiSNP (51) and excluded those with log Bayes factor ,10,
length ,100 kb or .10 Mb. We excluded samples with more
than 10 CNVs in total, with more than 10 Mb of total CNV
length, or failed SNP quality control. This identified the same
four individuals as the only PAK7 duplication carriers across dif-
ferent arrays and calling algorithms. For the additional European
ancestry cohorts, CNV calls were made as described in the
primary publications [see Supplementary Material, Table S1
and references (5,9,48,49)]. The CLOZUK calling method is
described in Guha et al. (2013) (52).
CNV analysis
We conducted a gene-based analysis using gene boundaries from
UCSC Genome Browser refGene (hg18) and identified 2653
genes impacted (from the transcription start to end point) by a
CNV (.100 kb but ,10 Mb) in at least one individual. Three
hundred eighty-two genes had at least four overlapping CNVs
(required to achieve P , 0.05) in the discovery data, represent-
ing a smaller number of loci, as some CNVs overlap multiple
genes. Fisher’s exact tests were used to calculate P-values in
the discovery analysis and a fixed-effects CMH test to assess
the evidence across replication cohorts.
Haplotype analysis
We analyzed carriers of the ‘common’ PAK7 duplication at
chr20:9,685,413–9,831,947, which is carried by 27 of 32 indivi-
duals with duplications overlapping the PAK7 locus in the
British Isles samples. Haplotype analysis used a core set of Affy-
metrix SNPs that had been genotyped in 23 of the samples and all
genotype data were converted to the forward strand. The four
samples omitted were from the CLOZUK sample genotyped
on Illumina where no suitable proxy SNPs were available for
analysis. From HapMap data, the start of the duplication sits in
a haplotype block that extends from rs2423462 (9682770) to
rs2423467 (9689876). The part of this block that is outside the
region, termed Hap Block 1 is from rs2423462 (9682770) to
rs742450 (9684493). The duplication ends in a region between
haplotype blocks. Immediately, 3′ of the duplication is a haplo-
type block that extends from rs6057009 (9840327) to rs6118819
(9867572) (Hap Block 2). We have focused on haplotypes
outside the duplication region, to analyze diploid genotypes,
and limited the analysis to regions of high LD where haplotypes
could be phased. In the absence of family data, extended haplo-
types outside these local blocks could not be accurately phased.
Haplotype frequencies and phased haplotypes, with a probabil-
ity .0.98, were estimated using the –hap and –hap-phase
functions in Plink (see Supplementary Material, Tables S6 and
S7). For either Hap Block, the chances that all 23 samples
would carry at least one copy of a specific haplotype, i.e. be
either heterozygous or homozygous for this haplotype q ¼ [q2
(probability of homozygous q) + 2∗q∗(12 q) (probability of
homozygous q)]23 ¼ (2q2 q2)23 where q is the haplotype fre-
quency. This probability was calculated for both Hap Blocks
and in the absence of LD between the blocks, these numbers
were multiplied together to determine the combined probability
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of all 23 carriers carry copies of the same haplotypes either side
of the duplication.
CNV breakpoint sequencing
Using an Agilent custom designed CGH microarray with high
probe density in the PAK7 region, we confirmed the duplication
event in one individual and the breakpoints identified by CGH
(chr20:9,684,902–9,833,151) map closely to those predicted
by the SNP array analyses (chr20:9,685,413–9,831,947; Sup-
plementary Material, Fig. S4). Based on these estimated break-
points and assuming that this is a tandem duplication that is
not inverted, we attempted to sequence from one copy of the du-
plication into the second copy in order to identify the precise
breakpoints. Using a forward primer positioned at the end of
the duplication (TCTCTGTTGGATGGAGCTTCT) and a
reverse primer positioned at the start of the duplication
(CGATGTAAAAAGACACAAGAGAAA), we successfully
PCR-amplified this unique region in a carrier sample. The
PCR did not amplify in noncarrier samples. Using capillary se-
quencing, we identified the event as being a tandem duplication
of 148 951 bp at chr20:9,684,767–9,833,717(hg18) with a
15 bp sequence inserted between the first and second copies of
the repeated sequence (Fig. 2).
Functional analysis
Protein extraction
Synaptoneurosome preparation was performed from full mouse
brain at P8–10 as described elsewhere with modifications (53).
Briefly, brain tissue was glass/glass homogenized in ice-cold
lysis buffer daily-fresh made until complete lysis. The protein
extraction buffer contained 10 mM Tris Base, 0.1 M sodium
chloride, 4 mM EDTA, 0.1% NP40 and was added with protease
inhibitor cocktail (Roche Diagnostic). The homogenate was cen-
trifuged at 1000g × 10 min at 48C in order to separate heavy cel-
lular membranes. The resulting supernatant was passed through
two 105 mm polypropylene mesh (Amazon, USA) and a 5 mm
nitrocellulose filter (Millipore) and finally centrifuged at
1000 g × 15 min at 48C. The obtained synaptoneurosomal-
depleted supernatant contains cytoplasmic proteins and was
collected in fresh tubes; while the pellet, which is enriched in
synaptoneurosomal proteins, was resuspended in protein extrac-
tion buffer. Protein concentration was measured by spectropho-
tometer quantification (Nanodrop, ND8000) in both cytoplasmic
and synaptoneurosomal-enriched extracts for further analysis.
Western blot was carried out by standard procedures with the
following specifications: protein samples were fractioned
through 8 or 10% acrylamide gel and blotted onto PVDF mem-
brane. The membrane was probed overnight with antibody
anti-MAP2 (mouse monoclonal, Millipore, MAB3418,
1:2500) and antibody anti-PSD95 (rabbit polyclonal, Cell Sig-
naling Technology, 2507, 1:2500). Antibody anti-b-actin
(rabbit polyclonal, Cell Signaling Technology, 4967, 1:5000)
was used as a loading control. After 16 h, three washes of
5 min with 0.5% Tween/TBS were carried out followed by 1 h
incubation with the following secondary antibodies: anti-mouse
HRP-linked IgG (Cell Signaling Technology, 7076, 1:10 000)
and anti-rabbit HRP-linked IgG (Cell Signaling Technology,
7074, 1:10 000). After washing as above, ECL substrate
(Millipore) was applied and chemiluminescent signal was
revealed by exposing photographic film (Sigma, Z370398) to
the membrane for 5 min.
Co-immunoprecipitation
Co-immunoprecipitation procedure was adapted from Felli et al.
(2005) (54) as described below. Synaptoneurosomal protein
extracts were made from full brain tissue as described and
PAK7 was immunoprecipitated. For both experiments,
500 ml-volume samples containing 1000 mg of synaptoneuroso-
mal extracts were obtained by dilution in protein extraction
buffer. Samples were immunoprecipitated with either 4 mg anti-
body anti-PAK7 (polyclonal goat, S-16, Santa Cruz Biotechnol-
ogy, sc-22155) or 4 mg antibody anti-DISC1 (polyclonal goat,
N-16, Santa Cruz Biotechnology, sc-47990). Normal goat
IgGs (Sigma, I5256) were used as a negative control. After
16 h, all samples were incubated with 25 ml of beads (protein
A/G PLUS-Agarose, Santa Cruz Biotechnology, sc-2003) for
4 h and washed. Samples were then resolved by western blotting
as described, and probed with antibody anti-DISC1 (rabbit poly-
clonal antibody anti-DISC1 Mid, Invitrogen, 40–6900, 1:1500)
or anti-PAK7 (polyclonal rabbit anti-PAK7, Sigma,
SAB3500335, 1:1000). Primary antibody incubation was fol-
lowed by incubation with biotinylated anti-rabbit IgG (Vector
Labs, BA-1000, 1:3000) and amplification with Vectastain
ABC kit (Vector Labs, PK-6100).
Free floating immunohistochemistry
For histological staining, brain tissue from mice at three different
developmental stages was used: P7 (postnatal day 7) andP . 60.
The brains, previously fixed in 4%paraformaldehyde/PBS and
kept in 20%sucrose/PBS at 48C, were sliced using a vibratome
(Leica) to obtain 50 mm-thick coronal sections. After 5 min in-
cubation with 0.1% hydrogen peroxide, sections were washed
in PBS, and moved for 1 h into a PBS blocking buffer containing
10% goat serum and 3% Triton for tissue permeabilization. Sec-
tions were then incubated for 36 h in blocking buffer added
with the following primary antibodies: anti-PAK7 (polyclonal
goat, Santa Cruz Biotechnology, sc-22155, 1:750), anti-DISC1
(polyclonal rabbit, Invitrogen, 40–6900, 1:500), anti-Synapsin
1/2 (polyclonal guinea pig, Synaptic Systems, 106 004,
1:1000). Primary antibody probing was followed by several
PBS washes for a total time of 2 h. Sections were then moved
to a secondary antibodies solution made of 0.05%Triton-X100
and added with the following fluorofore-conjugated antibodies:
DyLight 488 donkey anti-goat IgG (Jackson ImmunoResearch
Labs, 705-485-003, 1:500), DyLight 649 goat anti-rabbit IgG
(Jackson ImmunoResearch Labs, 111-495-003, 1:500) and
Cy3 goat anti-guinea pig IgG (Jackson ImmunoResearch Labs,
106-165-003, 1:500). After 2 h, sections were washed for
15 min in PBS and mounted onto microscope slides using
media containing DAPI (Vector H-1200). Co-immunostaining
of PAK7 and DISC1 was confirmed by confocal microscope
imaging (Zeiss, ×63 objective) in hippocampus and brain
cortex fields at each considered age.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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